Researchers in the Netherlands are making the case for routine whole-genome sequencing (WGS) for cancer patients, arguing that broad testing yields a high rate of clinically actionable findings versus panel-based approaches. In a Nature Medicine study, the group reported that 73% of patients had at least one clinically actionable biomarker, and WGS identified clinically relevant results in 41%—including targeted biomarkers, pathogenic germline variants, or clarification of diagnosis/tumor type. The analysis used real-world data from 888 patients at the Netherlands Cancer Institute in Amsterdam, with sequencing performed at the Hartwig Medical Foundation and comparisons to common panel workflows. For clinical operations, the data directly inform whether labs and payers should standardize WGS as an upfront test or keep relying on smaller targeted assays for specific mutations.